Trial intelligence / Profile preview

Reinduction with liposomal anthracyclines and capecitabine in HER2-negative locally advanced breast cancer with residual disease after neoadjuvant chemotherapy

2009-011756-22Phase 2Active

Sponsor
Azienda Ospedaliero Universitaria di Cagliari
Start
Jun 2009
Modality
DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of doxorubicin and capecitabine in breast cancer, sponsored by Azienda Ospedaliero Universitaria di Cagliari. Primary endpoints: Disease-free survival at 3 years, Overall survival at 3 years and 2 more. Started Jun 2009; status: active.

02

Drugs

doxorubicincapecitabine
03

Conditions

breast cancer

Beyond the preview

Go deeper on 2009-011756-22.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-011756-22.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call